Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).

Timeline

Start

2020-01-20

Primary completion

2022-12

Completion

2023-01

Drugs

Indications